Sequent Scientific Limited announced that the composite scheme of amalgamation amongst Sequent Scientific Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited has become effective from December 16, 2025. As part of the scheme, Sequent Scientific Limited has approved the allotment of 18,19,21,827 equity shares of face value ₹2 each to the shareholders of Viyash Life Sciences Private Limited, based on a share exchange ratio of 56 equity shares of Sequent for every 100 equity shares of Viyash. This allotment will increase the company's issued and paid-up equity share capital from ₹50.82 crore to ₹87.21 crore. The newly allotted shares will be listed on BSE and NSE in due course. Additionally, the company approved the allotment of 2,03,41,257 share warrants to Viyash warrant holders at an issue price of ₹181.94 per warrant. Sequent has received ₹92.52 crore as upfront payment, representing 25% of the issue price. Each warrant is convertible into one equity share of Sequent, subject to the receipt of the balance consideration of ₹277.57 crore. The Board of Directors also approved significant changes in management, effective December 16, 2025: Dr. Haribabu Bodepudi has been appointed as the Managing Director and Group Chief Executive Officer for two years, subject to shareholder approval. Mr. Rajaram Narayanan's designation has changed to Wholetime Director, designated as Chief Executive Officer – Animal Health, for the remaining tenure of his existing term. Mr. Srinivas Vasireddy has been appointed as an Additional Director (Wholetime and Non-Independent) for two years, also subject to shareholder approval. Furthermore, Mr. Ramakant Singani will take over as Chief Financial Officer and Key Managerial Personnel from January 1, 2026, while Mr. Saurav Bhala's resignation from the same role, effective January 1, 2026, was noted. CA Hull Investments has become a promoter of Sequent. The company's authorized share capital has been increased to ₹886.15 crore, divided into 4,43,07,35,000 equity shares of ₹2 each, with corresponding amendments to the Memorandum and Articles of Association. Sequent Research Limited ceased to be a wholly-owned subsidiary, and Appco Pharma LLC became a material subsidiary.
